Sign In
Buy DMTK
$0.0940
+0 (+0%)
At Close: Oct 21, 2024
DermTech Announces Release Date for Fourth-Quarter 2022 Financial Results
08:30am, Friday, 10'th Feb 2023
LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, will host a
DermTech: Momentum Rising With TRICARE
05:59am, Sunday, 22'nd Jan 2023
The company's skin diagnostic test, dubbed DMT, has an uncanny ability to pick up the highly prevalent skin cancer, melanoma. Commercialization has been modest due to various launch barriers. Neverthe
This Under-the-Radar Stock Has Tripled in 2023 -- and Could Have More Room to Run
05:55am, Wednesday, 18'th Jan 2023
This beaten-down healthcare stock has started the new year off with a bang.
DermTech, Inc. (DMTK) Reports Q3 Loss, Misses Revenue Estimates
07:36pm, Thursday, 03'rd Nov 2022
DermTech, Inc. (DMTK) delivered earnings and revenue surprises of 3.03% and 26.39%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
DermTech, Inc. (DMTK) Q3 2022 Earnings Call Transcript
06:42pm, Thursday, 03'rd Nov 2022
DermTech, Inc. (NASDAQ:DMTK ) Q3 2022 Earnings Conference Call November 3, 2022 5:00 PM ET Company Participants Steve Kunszabo - Head of IR John Dobak - President and CEO Kevin Sun - CFO Conference Ca
Diving Into DermTech
11:56am, Thursday, 01'st Sep 2022
Today, we take our first look at DermTech, Inc., a small molecular testing concern. The company is seeing some sales traction and the stock sells for less than cash value, but DermTech's cash burn rat
DermTech, Inc. (DMTK) CEO John Dobak on Q2 2022 Results - Earnings Call Transcript
09:56pm, Monday, 08'th Aug 2022
DermTech, Inc. (NASDAQ:DMTK ) Q2 2022 Earnings Conference Call August 8, 2022 5:00 PM ET Company Participants Steve Kunszabo - Head of Investor Relations John Dobak - President & Chief Executive Offic
Earnings Preview: DermTech, Inc. (DMTK) Q2 Earnings Expected to Decline
11:37am, Monday, 01'st Aug 2022
DermTech, Inc. (DMTK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
DermTech to Present on Genomic Innovation in Dermatology at AHIP 2022
04:05pm, Tuesday, 14'th Jun 2022
LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today announ
DermTech: Approaching An All Or Nothing Moment
12:27pm, Monday, 13'th Jun 2022
DermTech (DMTK) has transformative solutions that are more effective and accurate than traditional biopsy-based diagnostic approaches for detecting Skin Cancer. Commercialization of its proprietary Sm
DermTech to Present at the William Blair Growth Stock Conference
04:05pm, Wednesday, 01'st Jun 2022
LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today announ
DermTech, Inc. (DMTK) CEO John Dobak on Q1 2022 Results - Earnings Call Transcript
08:57pm, Tuesday, 03'rd May 2022
DermTech, Inc. (NASDAQ:DMTK ) Q1 2022 Earnings Conference Call March 3, 2022 5:00 PM ET Company Participants John Dobak – President and Chief Executive Officer Kevin Sun – Chief Financial Officer
DermTech, Inc. (DMTK) Reports Q1 Loss, Misses Revenue Estimates
06:49pm, Tuesday, 03'rd May 2022
DermTech, Inc. (DMTK) delivered earnings and revenue surprises of -18.82% and 1.28%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
DermTech, Inc.''s (DMTK) CEO John Dobak on Q4 2021 Results - Earnings Call Transcript
02:45am, Wednesday, 02'nd Mar 2022 Seeking AlphaDermTech, Inc.'s (DMTK) CEO John Dobak on Q4 2021 Results - Earnings Call Transcript
09:45pm, Tuesday, 01'st Mar 2022
DermTech, Inc.'s (DMTK) CEO John Dobak on Q4 2021 Results - Earnings Call Transcript
